NOTTINGHAM, UK – 16 June, 2021 – Life Science Newswire – Leading Drug Discovery Contract Research Organisation Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials.
Their experienced drug-hunters possess all the professional skills and know-how required to undertake the most demanding of research programs, and drive them from target validation through hit identification, hit-to-lead and lead optimization to pre-clinical development candidate. Sygnature’s in vivo pharmacology arm was formed by the incorporation of RenaSci, acquired in 2018, into Sygnature’s fully integrated drug discovery platform. In 2020 Sygnature added to this with the acquisitions of in vivo oncology firm Alderley Oncology and DMPK provider XenoGesis.
Since 2011, 34 compounds discovered by Sygnature for customers have entered pre-clinical development and, so far, 17 of these have progressed to clinical trials (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade, and in the last year has won both the Medilink Outstanding Achievement Award and the Bionow Company of the Year Award.
For further information, visit www.sygnaturediscovery.com
Director of Marketing
Phone: +44 (0)115 941 5401